{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Andrade Victor"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-ECPF-GEOD-26544"],"project":["EurocanPlatform"],"abstract":["Introduction: Peri-operative window trials, using molecular biomarkers as surrogate endpoints for treatment response, offer investigators a uniqueopportunity to obtain intact tumor samples at 2 different time-points and thus evaluate potential biomarkers over a short period of time. Here we report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected after a 10-day exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared to untreated controls. Methods: Paired tumor samples (biopsy and surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1mg/dy) for 10 days immediately prior to surgery (13 cases) or no treatment (13 controls). 502 cancer-rela"],"repository":["biostudies-other"],"experiment_type":["transcription profiling by array"],"data_source":["EurocanPlatform"],"pubmed_authors":["Sakr Rita","Patil Asawari","Qin Li-Xuan","Arroyo Crispinita","Brogi Edi","Morrogh Mary","Olshen Adam","Andrade Victor","King Tari","Morrow Monica","Mo Quianxing"],"additional_accession":[]},"is_claimable":false,"name":"Differentially expressed genes in window trials are influenced by the wound healing process: lessons learned from a pilot study with Anastrozole","description":"Introduction: Peri-operative window trials, using molecular biomarkers as surrogate endpoints for treatment response, offer investigators a uniqueopportunity to obtain intact tumor samples at 2 different time-points and thus evaluate potential biomarkers over a short period of time. Here we report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected after a 10-day exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared to untreated controls. Methods: Paired tumor samples (biopsy and surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1mg/dy) for 10 days immediately prior to surgery (13 cases) or no treatment (13 controls). 502 cancer-rela","dates":{"release":"2016-04-14T13:52:25Z","modification":"2016-04-14T13:52:25Z","creation":"2016-04-14T13:52:25Z"},"accession":"S-ECPF-GEOD-26544","cross_references":{"GEO":["GSE26544"],"ArrayExpress":["E-GEOD-26544"],"EFO":["EFO_0000635","EFO_0000305"],"ArrayExpress files":["E-GEOD-26544"]}}